Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Fluoroscopically-guided Versus Landmark-guided Sacroiliac Joint Injections

5. februar 2018 opdateret af: Johns Hopkins University

Randomized, Controlled, Double-blind, Comparative-effectiveness Study Comparing Fluoroscopically-guided and Landmark-guided Sacroiliac Joint Injections

In this study, the investigators are attempting to determine whether intra- or extra-articular injections are more effective; the relative prevalence rate of intra-articular and extra-articular SI joint pain; and the accuracy of extra-articular injections using fluoroscopy as the reference standard. 124 consecutive patients with mechanical low back pain below L5, tenderness overlying the SI joint(s) and at least 3 positive provocative maneuvers will be randomized to receive SI joint injections by 2 different approaches.

Group 1 will receive fluoroscopically-guided injections into the joint. Group 2 will receive landmark-guided injections into the tender area around the joint. In order to determine whether the injection in group 2 was intra-articular or extra-articular, an x-ray will be done after the injection to ascertain the location of contrast spread. The primary outcome measure will be pain relief at 1-month. Patients who obtain benefit at 1-month will be followed at 3-months, while those who fail to obtain benefit will exit the study to receive alternative care.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

125

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Forenede Stater
    • California
      • San Diego, California, Forenede Stater
        • Naval Hospital-San Diego
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21205
        • Johns Hopkins Hospital
      • Rockville, Maryland, Forenede Stater, 20889
        • Walter Reed National Military Medical Center
    • Pennsylvania
      • Hershey, Pennsylvania, Forenede Stater, 17033
        • Penn State

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 100 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Age > 18;
  2. Low back pain principally below the L5 vertebra;
  3. Three out of 6 positive SI joint provocative maneuvers;
  4. Agreed to undergo SI joint injection for diagnostic/ therapeutic purposes;
  5. Average pain score > 3/10 over the past week;
  6. Pain duration > 6 weeks;

Exclusion Criteria:

  1. Previous SI joint injection;
  2. Leg pain > back pain or lower leg pain > upper leg pain
  3. Active inflammatory spondyloarthropathy (e.g. ankylosing spondylitis);
  4. Untreated coagulopathy;
  5. Allergy to contrast dye or bupivacaine;
  6. Pain > 20 years in duration;
  7. Poorly controlled psychiatric (e.g. PTSD) or medical (congestive heart failure) condition

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: X-ray guided intra-articular injection
Injection of 40 mg depomethylprednisolone and 2 ml 0.5% bupivacaine into the SI (sacroiliac joint) cavity under fluoroscopic guidance
Procedure: X-ray SI joint steroid injection
Injection of steroid and local anesthetic into the joint cavity using fluoroscopic guidance
Aktiv komparator: Landmark-guided SI joint injection
Injection of 40 mg depomethylprednisolone and 2 ml 0.5% bupivacaine at the point of maximal tenderness (3 ml)
Procedure: Landmark-guided SI steroid injection
Injection of steroid into the joint area based on palpation. The injection may be inside the joint (intra-articular) or outside the joint in the ligaments (extra-articular)

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Average Back Pain at 1 Month Measured Using the Numeric Pain Scale
Tidsramme: 1 month from the start of treatment
This outcome measure compares the average back pain at baseline to the average back pain 1 month after the start of treatment. This is measured using the Numeric Pain Scale. The Numeric Pain Scale ranges from 0-10. 0 being no pain at all and 10 being the worst imaginable pain possible. The group receiving fluoroscopically-guided intra-articular injection is compared to the group receiving landmark-guided injections.
1 month from the start of treatment

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Resultater relateret til handicap målt ved 1 måned ved hjælp af Oswestry Disability Index
Tidsramme: 1 måned efter behandlingsstart
Funktionel kapacitet målt ved hjælp af Oswestry handicapindeks. Rækken af ​​mulige scores for Oswestry Disability Index er 0-100. 0 er lig med ingen handicap, og 100 er den maksimalt mulige handicap.
1 måned efter behandlingsstart
Resultater relateret til handicap målt efter 3 måneder ved hjælp af Oswestry Disability Index
Tidsramme: 3 måneder efter behandlingsstart
Funktionel kapacitet målt ved hjælp af Oswestry handicapindeks. Rækken af ​​mulige scores for Oswestry Disability Index er 0-100. 0 er lig med ingen handicap, og 100 er den maksimalt mulige handicap.
3 måneder efter behandlingsstart
Worst Back Pain at 1 Month Measured Using the Numeric Pain Scale
Tidsramme: 1 month from the start of treatment
This outcome measure compares the worst back pain at baseline to the worst back pain at 1 months after the start of treatment. This is measured using the Numeric Pain Scale. The Numeric Pain Scale ranges from 0-10. 0 being no pain at all and 10 being the worst imaginable pain possible. The group receiving fluoroscopically-guided intra-articular injection is compared to the group receiving landmark-guided injections.
1 month from the start of treatment
Average Back Pain at 3 Months Measured Using the Numeric Pain Scale
Tidsramme: 3 months from the start of treatment
This outcome measure compares the average back pain at baseline to the average back pain at 3 months after the start of treatment. This is measured using the Numeric Pain Scale. The Numeric Pain Scale ranges from 0-10. 0 being no pain at all and 10 being the worst imaginable pain possible. The group receiving fluoroscopically-guided intra-articular injection is compared to the group receiving landmark-guided injections.
3 months from the start of treatment
Worst Back Pain at 3 Months Measured Using the Numeric Pain Scale
Tidsramme: 3 months after the start of treatment
This outcome measure compares the worst back pain at baseline to the worst back pain at 3 months after the start of treatment. This is measured using the Numeric Pain Scale. The Numeric Pain Scale ranges from 0-10. 0 being no pain at all and 10 being the worst imaginable pain possible. The group receiving fluoroscopically-guided intra-articular injection is compared to the group receiving landmark-guided injections.
3 months after the start of treatment
Patient satisfaction of the procedure at 1 month measured using the Likert Scale
Tidsramme: 1 month
Patient satisfaction is measured at 1 month after the procedure using the Likert Scale. The range of possible scores for the Likert Scale are 1-5. I being very unsatisfied and 5 being very satisfied.
1 month
Patient satisfaction of the procedure at 3 months measured using the Likert Scale
Tidsramme: 3 months
Patient satisfaction is measured at 1 month after the procedure using the Likert Scale. The range of possible scores for the Likert Scale are 1-5. I being very unsatisfied and 5 being very satisfied.
3 months
Positive categorical outcome
Tidsramme: 1 month
Decrease in average back pain score at 1 month of greater or equal to 2 points coupled with a satisfaction score > 3 on a 1-5 scale
1 month
Positive categorical outcome
Tidsramme: 3 months
Decrease in average back pain score at 3 months of greater or equal to 2 points coupled with a satisfaction score > 3 on a 1-5 scale
3 months
Positive diagnostic blocks
Tidsramme: 6 hours
The percentage of participants who experience greater or equal to 50% pain relief based on their pain diary
6 hours

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Johns Hopkins University

Samarbejdspartnere

Milton S. Hershey Medical Center
United States Naval Medical Center, San Diego
Walter Reed National Military Medical Center
Uniformed Services University of the Health Sciences

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. maj 2014

Primær færdiggørelse (Faktiske)

1. november 2017

Studieafslutning (Faktiske)

1. november 2017

Datoer for studieregistrering

Først indsendt

22. marts 2014

Først indsendt, der opfyldte QC-kriterier

25. marts 2014

Først opslået (Skøn)

26. marts 2014

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

7. februar 2018

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. februar 2018

Sidst verificeret

1. februar 2018

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • NA_00092414

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner